Correlation between common clinical outcome parameters, CTC-changes and ARV7-status (androgen receptor splice variant 7) in patients with mCRPC treated with first line abiraterone acetat (Zytiga®).

Trial Profile

Correlation between common clinical outcome parameters, CTC-changes and ARV7-status (androgen receptor splice variant 7) in patients with mCRPC treated with first line abiraterone acetat (Zytiga®).

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Abiraterone acetate (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms STAR-V7
  • Most Recent Events

    • 16 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top